IL6 and COVID-19: Immune dysregulation is reasonably believed to be driven by IL-6 level changes in patients with COVID-19, characterized by a cytokine storm. Scientific evidence shows that high serum IL-6 results in immune defects such as lymphopenia, impaired lymphocyte cytotoxicity, and endothelial activation.